The ClarIDHy phase III multicenter trial randomized 185 patients with IDH1-mutated cholangiocarcinoma (91.4% ICC) that had progressed on standard chemotherapy to either ivosidenib or placebo [47]. Here, IDH1 is linked to intrahepatic cholangiocarcinoma.